SCHEMBL10243017

SCHEMBL10243017

CCNC(=O)OCc1cccc(C#N)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 2/20 0.48
FFAR4 Q5NUL3 1/20 0.48
MEP1A Q16819 1/20 0.45
MEP1B Q16820 1/20 0.45
BTK Q06187 2/20 0.44
ERCC1 P07992 1/20 0.44
ERCC4 Q92889 1/20 0.44
CTSL P07711 1/20 0.44
CTSB P07858 1/20 0.44
CTSS P25774 1/20 0.44
CTSK P43235 1/20 0.44
MAOB P27338 1/20 0.43
MRGPRX4 Q96LA9 2/20 0.43
GRIA2 P42262 1/20 0.43
GRIN1 Q05586 1/20 0.43
GRIN2A Q12879 1/20 0.43
LMNA P02545 1/20 0.43
CNR1 P21554 1/20 0.43
GLA P06280 1/20 0.43
KCNH2 Q12809 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2659356 0.81 ALDH1A1 (0.56) FFAR1FFAR4MEP1AMEP1BMAOB
SCHEMBL14233717 0.80 LMNA (0.45) LMNAMAPTL3MBTL1
SCHEMBL20954353 0.79 FFAR1 (0.49) FFAR1FFAR4MEP1AMEP1BBTK
SCHEMBL14162421 0.78 GLA (0.52) FFAR1FFAR4MEP1AMEP1BMAOB
SCHEMBL10243039 0.78 LMNA (0.44) LMNAMAPTL3MBTL1
SCHEMBL25852781 0.78 HCAR2 (0.54) MAOBL3MBTL1
SCHEMBL10242970 0.78 GLA (0.54) MAOBGLA
SCHEMBL16439821 0.78 FFAR1 (0.53) FFAR1FFAR4MEP1AMEP1BERCC1
SCHEMBL14783862 0.78 FFAR1 (0.53) FFAR1FFAR4MEP1AMEP1BMAOB
SCHEMBL16150588 0.78 ALDH1A1 (0.56) FFAR1FFAR4MEP1AMEP1BMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 FFAR1 3191/4885FFAR4 3884/4885MEP1A 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.